The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
Open accessAbstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and agonistic antibodies against TRAIL death receptors (DR) kill tumor cells while causing virtually no damage to normal cells. Several novel drugs targeting TRAIL receptors are currently in clinical trials. However, TRAIL resistance is a common obstacle in TRAIL-based therapy and limits the efficiency of these drugs. In this review article we discuss different mechanisms of TRAIL resistance, and how they can be predicted and therapeutically circumvented. In addition, we provide a brief overview of all TRAIL-based clinical trials conducted so far. It is apparent that although the effects of TRAIL therapy are disappointingly modest overall, a small subset of patients responds very well to TRAIL. We argue that the true potential of targeting TRAIL DRs in cancer can only be reached when we find efficient ways to select for those patients that are most likely to benefit from the treatment. To achieve this, it is crucial to identify biomarkers that can help us predict TRAIL sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Apoptosis control by death and decoy receptors
Ashkenazi, A., & Dixit, V. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80034-9 · Cited by 1,288
Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G. S., & Green, D. R. (2011) · Nature · doi:10.1038/nature09852 · Cited by 1,278
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Cretney, E., Takeda, K., Yagita, H., Glaccum, M., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 616
Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
TRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, E., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim, K., Fisher, M. J., Xu, S., & El‐Deiry, W. S. (2000) · PubMed · Cited by 376
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Kim, Y., Suh, N., Sporn, M., & Reed, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202458200 · Cited by 309
Cell surface Death Receptor signaling in normal and cancer cells
Özören, N., & El-Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 289
c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis
Golks, A., Brenner, D., Fritsch, C., Krammer, P. H., & Lavrik, I. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414425200 · Cited by 282
cFLIP regulation of lymphocyte activation and development
Budd, R. C., Yeh, W.-C., & Tschopp, J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1787 · Cited by 280
Ehrhardt, H., Fulda, S., Schmid, I., Hiscott, J., Debatin, K.-M., & Jeremias, I. (2003) · Oncogene · doi:10.1038/sj.onc.1206520 · Cited by 272
Soria, J.-C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N., Smethurst, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 246
Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
Ricci, M. S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D. T., & El-Deiry, W. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8541-8555.2004 · Cited by 243
Jin, Z., McDonald, E. R., Dicker, D. T., & El-Deiry, W. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405538200 · Cited by 237
Micalizzi, D. S., Christensen, K. L., Jedlicka, P., Coletta, R. D., Barón, A. E., Harrell, J. C., Horwitz, K. B., Billheimer, D., Heichman, K. A., Welm, A. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37815 · Cited by 232
Self-citationSoria, J.-C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.-P., Reese, D., Wiezorek, J., & Blackhall, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4847 · Cited by 231
Pop, C., Oberst, A., Drag, M., Van Raam, B. J., Riedl, S. J., Green, D. R., & Salvesen, G. S. (2011) · Biochemical Journal · doi:10.1042/bj20101738 · Cited by 226
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., Emme, D., Röder, C., Kalthoff, H., & Wajant, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209719 · Cited by 219
Taniai, M., Grambihler, A., Higuchi, H., Werneburg, N., Bronk, S. F., Farrugia, D. J., Kaufmann, S. H., & Gores, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2770 · Cited by 218
Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Oberst, A., Pop, C., Tremblay, A. G., Blais, V., Denault, J.-B., Salvesen, G. S., & Green, D. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.095083 · Cited by 214
TRAIL-R as a Negative Regulator of Innate Immune Cell Responses
Diehl, G. E., Yue, H. H., Hsieh, K., Kuang, A. A., Ho, M., Morici, L. A., Lenz, L. L., Cado, D., Riley, L. W., & Winoto, A. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.008 · Cited by 212
Nimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 201
Cummins, J. M., Kohli, M., Rago, C., Kinzler, K. W., Vogelstein, B., & Bunz, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0046 · Cited by 200
Kandasamy, K., Srinivasula, S. M., Alnemri, E. S., Thompson, C. B., Korsmeyer, S. J., Bryant, J., & Srivastava, R. K. (2003) · PubMed · Cited by 198
Hotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
The c-FLIP–NH2 terminus (p22-FLIP) induces NF-κB activation
Golks, A., Brenner, D., Krammer, P. H., & Lavrik, I. N. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051556 · Cited by 187
Sedger, L. M., Glaccum, M. B., Schuh, J. C. L., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P. J., Le, T., Goodwin, R. G., et al. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200208)32:8<2246::aid-immu2246>3.0.co;2-6 · Cited by 184
Psahoulia, F. H., Drosopoulos, K. G., Doubravska, L., Andera, L., & Pintzas, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0001 · Cited by 179
MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers
Imam, J. S., Buddavarapu, K., Lee-Chang, J. S., Ganapathy, S., Camosy, C., Chen, Y., & Rao, M. K. (2010) · Oncogene · doi:10.1038/onc.2010.233 · Cited by 174
McCoy, E. L., Iwanaga, R., Jedlicka, P., Abbey, N.-S., Chodosh, L. A., Heichman, K. A., Welm, A. L., & Ford, H. L. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37691 · Cited by 172
Self-citationGreco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
Ford, H. L., Kabingu, E. N., Bump, E. A., Mutter, G. L., & Pardee, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12608 · Cited by 165
Self-citationPlaying the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer
Pennarun, B., Meijer, A., de Vries, E. G. E., Kleibeuker, J. H., Kruyt, F., & de Jong, S. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.004 · Cited by 162
TRAIL receptor signaling and therapeutics
Abdulghani, J., & El‐Deiry, W. S. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.519701 · Cited by 161
Death Receptor Agonists as a Targeted Therapy for Cancer
Wiezorek, J., Holland, P., & Graves, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1692 · Cited by 160
Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies
Zerafa, N., Westwood, J. A., Cretney, E., Mitchell, S., Waring, P., Iezzi, M., & Smyth, M. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5586 · Cited by 159
Burns, T. F., & El‐Deiry, W. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103516200 · Cited by 157
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M. M., Fox, N. L., Miceli, R. C., Ullrich, S. J., Fisher, G. A., & Tolcher, A. W. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp292 · Cited by 157
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N. W., Kennedy, D. B., Dyer, M. J. S., & Cohen, G. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401649 · Cited by 156
Fricker, N., Beaudouin, J., Richter, P., Eils, R., Krammer, P. H., & Lavrik, I. N. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201002060 · Cited by 154
Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., Tomek, S., Horvat, R., Zeillinger, R., Zielinski, C. C., & Krainer, M. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0136 · Cited by 149
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
Herbst, R. S., Kurzrock, R., Hong, D. S., Valdivieso, M., Hsu, C., Goyal, L., Juan, G., Hwang, Y. C., Wong, S., Hill, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0631 · Cited by 144
Mellier, G., Huang, S., Shenoy, K., & Pervaiz, S. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.12.002 · Cited by 124
Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?
Lynch, H. T., Boland, C. R., Rodríguez-Bigas, M. A., Amos, C. I., Lynch, J. F., & Lynch, P. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3119 · Cited by 124
Leong, S., Cohen, R. B., Gustafson, D. L., Langer, C. J., Camidge, D. R., Padavic, K., Gore, L., Smith, M., Chow, L. Q. M., von Mehren, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7422 · Cited by 123
Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes
Ehrlich, S., Infante‐Duarte, C., Seeger, B., & Zipp, F. (2003) · Cytokine · doi:10.1016/s1043-4666(03)00094-2 · Cited by 116
Lee, T.-J., Um, H. J., Min, D. S., Park, J. W., Choi, K. S., & Kwon, T. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.03.022 · Cited by 108
Mom, C. H., Verweij, J., Oldenhuis, C. N. A. M., Gietema, J. A., Fox, N. L., Miceli, R. C., Eskens, F. A. L. M., Loos, W. J., de Vries, E. G. E., & Sleijfer, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0996 · Cited by 106
Kim, J. Y., Kim, E. H., Park, S. S., Lim, J. H., Kwon, T. K., & Choi, K. S. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21958 · Cited by 100
von Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Humphreys, R. C., Gribbin, M., Fox, N. L., & Camidge, D. R. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.005 · Cited by 99
Ng, C., & Bonavida, B. (2002) · PubMed · Cited by 98
Coletta, R. D., Christensen, K. L., Micalizzi, D. S., Jedlicka, P., Varella‐Garcia, M., & Ford, H. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3141 · Cited by 96
Self-citationPeták, I., Douglas, L., Tillman, D. M., Vernes, R., & Houghton, J. A. (2000) · PubMed · Cited by 95
Lipopolysaccharide Induces Expression of APO2 Ligand/TRAIL in Human Monocytes and Macrophages
Halaas, Vik, Ashkenazi, & Espevik (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00671.x · Cited by 95
Sayers, T. J., & Murphy, W. J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0676-3 · Cited by 93
Sinicrope, F. A., Penington, R. C., & Tang, X. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1289 · Cited by 91
Martin, S., Phillips, D. C., Szücs, K. S., Elghazi, L., Desmots, F., & Houghton, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1494 · Cited by 87
Karikari, C. A., Roy, I., Tryggestad, E., Feldmann, G., Pinilla, C., Welsh, K., Reed, J. C., Armour, E. P., Wong, J. W., Herman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0634 · Cited by 87
Song, J. H., Kandasamy, K., & Kraft, A. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802511200 · Cited by 84
Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R. C., & Thorburn, A. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704210200 · Cited by 83
Self-citationEarel, J. K., VanOosten, R. L., & Griffith, T. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3017 · Cited by 80
Lincz, L. F., Yeh, T.-X., & Spencer, A. G. (2001) · Leukemia · doi:10.1038/sj.leu.2402251 · Cited by 79
Shenoy, K., Wu, Y., & Pervaiz, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1996 · Cited by 77
Reis, C. R., van der Sloot, A. M., Natoni, A., Szegezdi, É., Setroikromo, R., Meijer, M., Sjollema, K. A., Stricher, F., Cool, R. H., Samali, A., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.61 · Cited by 74
Gillissen, B. F., Wendt, J., Richter, A., Richter, A. M., Müer, A., Overkamp, T., Gebhardt, N., Preißner, R., Belka, C., Dörken, B., et al. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200912070 · Cited by 72
Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice
Zheng, S. J., Jiang, J. K., Shen, H., & Chen, Y. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5652 · Cited by 71
Natoni, A., MacFarlane, M., Inoue, S., Walewska, R. J., Majid, A., Knee, D. A., Stover, D. R., Dyer, M. J. S., & Cohen, G. M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06852.x · Cited by 70
Makhov, P. B., Golovine, K. V., Uzzo, R. G., Rothman, J., Crispen, P. L., Shaw, T., Scoll, B. J., & Kolenko, V. M. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.106 · Cited by 69
Yee, L., Fanale, M. A., Dimick, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 68
Lü, J., McEachern, D., Sun, H., Bai, L., Peng, Y., Qiu, S., Miller, R. S., Liao, J., Han, Y., Liu, M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0864 · Cited by 67
BH3‐only proteins: The death‐puppeteer's wires
Ghiotto, F., Fais, F., & Bruno, S. (2009) · Cytometry Part A · doi:10.1002/cyto.a.20819 · Cited by 65
Henson, E. S., Gibson, E. M., Villanueva, J., Bristow, N. A., Haney, N., & Gibson, S. B. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10597 · Cited by 65
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor
Ray, S., Bucur, O., & Almasan, A. (2005) · APOPTOSIS · doi:10.1007/s10495-005-2490-y · Cited by 61
FLIP as an Anti-Cancer Therapeutic Target
Yang, J. K. (2008) · Yonsei Medical Journal · doi:10.3349/ymj.2008.49.1.19 · Cited by 60
LoRusso, P. M., Hong, D. S., Heath, E. I., Kurzrock, R., Wang, D., Hsu, M. L., Goyal, L., Wiezorek, J. S., Storgard, C. M., & Herbst, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3534 · Cited by 50
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Calvert, H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14006 · Cited by 49
Camidge, D. R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1167 · Cited by 48
Natoni, A., MacFarlane, M., Inoue, S., et al. (2007) · Figshare · doi:10.1111/j.1365-2141.2007.06852.x/abstract · Cited by 48
Stern, H. M., Padilla, M., Wagner, K., Amler, L. C., & Ashkenazi, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3108 · Cited by 43
Sikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Plummer, E. R., Calvert, H., Fox, N. L., Kumm, E., Jones, S. F., & Burris, H. A. (2007) · UCL Discovery (University College London) · Cited by 36
Yee, L., Burris, H. A., Kozloff, M. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4129 · Cited by 31
Overcoming TRAIL resistance in ovarian carcinoma
Bevis, K. S., Buchsbaum, D. J., & Straughn, J. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.034 · Cited by 30
von Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Kumm, E., Gallant, G., Fox, N., & Camidge, D. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba7501 · Cited by 25
Pacey, S., Plummer, R., Attard, G., Bale, C., Calvert, H., Blagden, S. P., Fox, N. L., Corey, A. E., & Bono, J. S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3055 · Cited by 23
Karapetis, C. S., Clingan, P., Leighl, N. B., Durbin-Johnson, B. P., O'Neill, V. J., & Spigel, D. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7535 · Cited by 20
TRAIL Receptor Signaling Regulation of Chemosensitivity In Vivo but Not In Vitro
Menke, C., Goncharov, T., Qamar, L., Korch, C. T., Ford, H. L., Behbakht, K., & Thorburn, A. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014527 · Cited by 15
Self-citationHorita, H. N., Thorburn, J., Frankel, A. E., & Thorburn, A. M. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9914-4 · Cited by 8
Self-citation
Cited by
Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics
Jan, R., & Chaudhry, G.-E.-S. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.024 · Cited by 899
A fate worse than death: apoptosis as an oncogenic process
Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451
Molecular aspects of cancer cell resistance to chemotherapy
Rebucci, M., & Michiels, C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.017 · Cited by 407
Maycotte, P., & Thorburn, A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14627 · Cited by 393
Self-citationJiang, G.-M., Tan, Y., Wang, H., Peng, L., Chen, H.-T., Meng, X.-J., Li, L.-L., Liu, Y., Li, W.-F., & Shan, H. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0944-z · Cited by 365
Metadata
- Authors
- Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L.
- Venue
- Oncogene
- Published
- 2012-05-14
- Volume
- 32
- Issue
- 11
- Pages
- 1341-1350
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2007718868
- Cited by
- 276
- References
- 100
- FWCI
- 11.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.